Want to see SE:ICO full AI Analyst Report?
ICO Stock Chart & Stats
kr1.03
kr0.03(3.00%)
At close: 4:00 PM EDT
kr1.03
kr0.03(3.00%)
Day’s Range― - ―
52-Week Rangekr0.87 - kr2.50
Previous CloseN/A
Volume15.90K
Average Volume (3M)67.87K
Market Cap
kr92.38M
Enterprise Valuekr68.18
Total Cash (Recent Filing)kr37.12M
Total Debt (Recent Filing)kr4.32M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding74,800,380
10 Day Avg. Volume46,702
30 Day Avg. Volume67,870
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)39.24
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.42
Revenue Forecast (FY)kr29.00M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe 31.15% TTM revenue increase indicates continued demand for Iconovo’s inhaler platforms and development capabilities. Sustained top-line growth can expand the partnered project base, support future milestone opportunities, and improve operating leverage if costs become better absorbed.
Conservative LeverageVery low leverage gives Iconovo greater financial flexibility than a highly indebted development company. The modest debt burden reduces balance-sheet pressure and leaves more capacity to fund platform development or absorb operating volatility while projects progress through development gates.
Platform-based Partnering ModelA portfolio of proprietary inhaler platforms allows Iconovo to support multiple partner programs across new and generic inhaled medicines. This asset-light partnering model can create recurring development, milestone, royalty, or supply income as successful projects advance toward commercialization.
Bears Say
Deeply Negative ProfitabilityLarge operating and net losses show that current revenue is not covering the company’s cost base. Persistently negative gross profit also points to poor cost absorption, leaving Iconovo without an established path to sustainable profitability even after the recent revenue rebound.
Material Cash ConsumptionSubstantial negative operating and free cash flow means Iconovo is consuming cash while developing its partnered programs. If losses persist, continued funding will be needed to maintain operations and advance projects, creating an ongoing constraint on strategic and financial flexibility.
Negative Shareholder ReturnsA roughly negative 28% return on equity indicates that shareholder capital is currently producing substantial losses rather than durable value creation. This weak capital productivity can persist until project economics and margins improve, increasing pressure to demonstrate profitable commercialization progress.
ICO FAQ
What was Iconovo AB’s price range in the past 12 months?
Iconovo AB lowest stock price was kr0.87 and its highest was kr2.50 in the past 12 months.
What is Iconovo AB’s market cap?
Iconovo AB’s market cap is kr92.38M.
When is Iconovo AB’s upcoming earnings report date?
Iconovo AB’s upcoming earnings report date is Oct 23, 2026 which is in 30 days.
How were Iconovo AB’s earnings last quarter?
Iconovo AB released its earnings results on Aug 20, 2026. The company reported -kr0.098 earnings per share for the quarter.
Is Iconovo AB overvalued?
According to Wall Street analysts Iconovo AB’s price is currently Overvalued.
Does Iconovo AB pay dividends?
Iconovo AB does not currently pay dividends.
What is Iconovo AB’s EPS estimate?
Iconovo AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iconovo AB have?
Iconovo AB has 74,800,380 shares outstanding.
What happened to Iconovo AB’s price movement after its last earnings report?
Iconovo AB reported an EPS of -kr0.098 in its last earnings report. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of Iconovo AB?
Currently, no hedge funds are holding shares in SE:ICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iconovo AB
Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.